SOCIOECONOMIC IMPACT OF EPIDERMOLYSIS BULLOSA ON PATIENTS, THEIR CAREGIVERS AND SOCIAL SECURITY SYSTEM IN THE CZECH REPUBLIC
Author(s)
Jakub Holcák, PharmD, Anna Jandová, MSc, Tereza Vávrová, MSc, Katarína Sokolová, MSc, Klara Lamblova, MSc, Tomáš Doležal, PhD, MD, Markéta Hašplová, MSc.
Value Outcomes by IQVIA, Prague, Czech Republic.
Value Outcomes by IQVIA, Prague, Czech Republic.
OBJECTIVES: Epidermolysis bullosa (EB) is a rare genetic condition causing blistering fragile skin and mucous membranes. Our study explores the socioeconomic burden of the disease and its impact on the quality-of-life (QoL) of patients and their caregivers.
METHODS: A cross-sectional questionnaire-based study was performed among Czech patients and their caregivers followed in the clinical center specialized in EB. We collected demographic, clinical and QoL data: EQ-5D-5L, disease specific QOLEB and ZBI (Zarit burden interview-caregiver burden), out-of pocket costs, foundation or patient organization costs and social security system costs. Productivity loss was assessed using patient’s working/school attendance status and questionnaire WPAI-GH. Disease-related impact on activities was assessed for both the patient and the caregiver.
RESULTS: Fifty EB patients completed the questionnaires (15% of the Czech EB population). The mean EB patient age was 24.9 years, 54.0% participants were male, mean utility from EQ-5D was 0.641 and mean QOLEB score was 13.2, corresponding to a moderate impact on the QoL of EB patients. EB patients on average absented from school 2.5 hours/week and total productivity loss for adults was 29.6%.Twenty-six caregivers for EB patients participated in the study with mean age 40.3 years and most were women (96.2%). The study revealed that disease impacted 64% of caregivers in their ability to work. ZBI scores were equal to 23.6 corresponding to mild to moderate burden. Total monthly out-of-pocket costs related to EB were 2,067 CZK (€85) mainly related to medication, cosmetics and medical supplies (56.7%), transport (28.3%) and rehabilitation (10.8%). Mean annual social security system costs spent on EB patients were 144,500 CZK (€5,967).
CONCLUSIONS: Our study revealed a significant societal burden imposed on EB patients and their caregivers. These costs should therefore not be omitted while assessing innovative and effective EB treatments.
METHODS: A cross-sectional questionnaire-based study was performed among Czech patients and their caregivers followed in the clinical center specialized in EB. We collected demographic, clinical and QoL data: EQ-5D-5L, disease specific QOLEB and ZBI (Zarit burden interview-caregiver burden), out-of pocket costs, foundation or patient organization costs and social security system costs. Productivity loss was assessed using patient’s working/school attendance status and questionnaire WPAI-GH. Disease-related impact on activities was assessed for both the patient and the caregiver.
RESULTS: Fifty EB patients completed the questionnaires (15% of the Czech EB population). The mean EB patient age was 24.9 years, 54.0% participants were male, mean utility from EQ-5D was 0.641 and mean QOLEB score was 13.2, corresponding to a moderate impact on the QoL of EB patients. EB patients on average absented from school 2.5 hours/week and total productivity loss for adults was 29.6%.Twenty-six caregivers for EB patients participated in the study with mean age 40.3 years and most were women (96.2%). The study revealed that disease impacted 64% of caregivers in their ability to work. ZBI scores were equal to 23.6 corresponding to mild to moderate burden. Total monthly out-of-pocket costs related to EB were 2,067 CZK (€85) mainly related to medication, cosmetics and medical supplies (56.7%), transport (28.3%) and rehabilitation (10.8%). Mean annual social security system costs spent on EB patients were 144,500 CZK (€5,967).
CONCLUSIONS: Our study revealed a significant societal burden imposed on EB patients and their caregivers. These costs should therefore not be omitted while assessing innovative and effective EB treatments.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE717
Topic
Economic Evaluation, Health Service Delivery & Process of Care, Patient-Centered Research
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Work & Home Productivity - Indirect Costs
Disease
Rare & Orphan Diseases